← Back to Search

Other

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Phase 1
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1, 2, 5, 15, 29, 43 and 60
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new eye injection treatment called MHU650 for people with macular edema. The goal is to see if it can reduce eye swelling and improve vision by delivering the medicine directly to the affected area.

Eligible Conditions
  • Macular Edema
  • Macular Degeneration
  • Diabetic Macular Edema
  • Cystoid Macular Edema
  • Retinal Vein Occlusion
  • Central Retinal Vein Occlusion

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1, 2, 5, 15, 29, 43 and 60
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 1, 2, 5, 15, 29, 43 and 60 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline in Best Correct Visual Acuity (BCVA ) by dose level and timepoint - Study Eye
Change from baseline in Central subfield thickness (CSFT) (µm) in the study eye by dose level and timepoint
Change from baseline in Intraocular pressure (IOP) (mmHg) in the study eye by dose level and timepoint
+1 more
Secondary study objectives
Pharmacokinetics of single dose of MHU650 - AUCinf
Pharmacokinetics of single dose of MHU650 - AUClast
Pharmacokinetics of single dose of MHU650 - Cmax
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment1 Intervention
Cohort 4, open-label, non-randomized, single administration
Group II: Cohort 3Experimental Treatment1 Intervention
Cohort 3, open-label; non-randomized, single administration
Group III: Cohort 2Experimental Treatment1 Intervention
Cohort 2; open-label, non-randomized, single administration
Group IV: Cohort 1Experimental Treatment1 Intervention
Cohort 1; open-label, non-randomized, single administration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MHU650
2020
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,921 Previous Clinical Trials
4,254,291 Total Patients Enrolled
37 Trials studying Macular Edema
43,553 Patients Enrolled for Macular Edema
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top